Researchers at the Medical College of Georgia at Augusta University are searching for a better way to understand why many men with prostate cancer end up with Alzheimer’s disease, and whether it’s the standard hormone therapy treatment or an overactive immune response that actually contributes to the problem.
ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease – Biotech Investments
EQS-News: ActiTrexx GmbH / Key word(s): Study ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease 19.03.2024 / 10:00 CET/CEST The